Aydın YAVUZ, Kürşat DİKMEN, Hasan BOSTANCI, Murat AKIN, Harun KARABACAK, Latife Arzu ARAL

Plasma human leukocyte antigen-G (HLA-G) in patients with thyroid cancer

Background/aim: A number of tumor markers detected in the serum or pathological specimens using immunohistochemical methods are used for early detection of malignancies and postoperative follow-up. Human leukocyte antigen-G (HLA-G) is a nonclassic HLA class I molecule. Recent studies suggested a relationship between HLA-G positivity and the stage or the phenotype of the malignancy. In this study, the relationship between serum HLA-G positivity and thyroid cancer was investigated. Materials and methods: Fifty patients with thyroid cancer and 45 healthy volunteers were included in this study. Serum HLA-G levels were measured using ELISA. Results: HLA-G was positive in only 3 out of 50 patients with thyroid cancer (2 papillary, 1 follicular type). On the other hand, HLA-G was positive in 20 out of 45 healthy subjects (P < 0.001). The prevalence of detectable levels of serum HLA-G was independent of sex and age in the whole study population. No correlation was found between serum HLA-G value and thyroid hormone profile, neither in papillary thyroid cancer nor follicular thyroid cancer patients. Conclusion: In this study, serum HLA-G was significantly less common in patients with thyroid cancer than in healthy controls.

PDF

___

1. Gocun PU, Karakus E, Bulutay P, Akturk M, Akin M, Poyraz A. What is the malignancy risk for atypia of undetermined significance? Three years experience at a university hospital in Turkey. Cancer Cytopathol 2014; 122: 604-610.
2. Urasevic M, Dummer R. HLA-G and IL-10 expression in human cancer--different stories with the same message. Semin Cancer Biol 2003; 13: 337-342.
3. de Figueiredo Feitosa NL, Crispim JC, Zanetti BR, Magalhães PK, Soares CP, SoaresEG, Neder L, Donadi EA, Maciel LM. HLA-G is differentially expressed in thyroid tissues. Thyroid 2014; 24: 585-592.
4. Nunes LM, Ayres FM, Francescantonio IC, Saddi VA, Avelino MA, Alencar Rde C, Silva RC, Meneghini AJ, Wastowski IJ. Association between the HLA-G molecule and lymph node metastasis in papillary thyroid cancer. Hum Immunol 2013; 74: 447-451.
5. Bainbridge D, Ellis S, Le Bouteiller P, Sargent I. HLA-G remains a mystery. Trends Immunol 2001; 22: 548-552.
6. Contini P, Ghio M, Poggi A, Filaci G, Indiveri F, Ferrone S, Puppo F. Soluble HLA-A, -B, -C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol 2003; 33: 125- 134.
7. Le Gal FA, Riteau B, Sedlik C, Khalil-Daher I, Menier C, Dausset J, Guillet JG, Carosella ED, Rouas-Freiss N. HLA-G mediated inhibition of antigen-specific cytotoxic T lymphocytes. Int Immunol 1999; 11: 1351-1356.
8. Ellis SA, Sargent IL, Redman CW, McMichael AJ. Evidence for a novel HLA antigen found on human extravillous trophoblast and a choriocarcinoma cell line. Immunology 1986; 59: 595- 601.
9. Wiendl H, Mitsdoerffer M, Hofmeister V, Wischhusen J, Weiss EH, Dichgans J, Lochmuller H, Hohlfeld R, Melms A, Weller M. The non-classical MHC molecule HLA-G protects human muscle cells from immune-mediated lysis: implications for myoblast transplantation and gene therapy. Brain 2003; 126: 176-185.
10. Urosevic M, Kurrer MO, Kamarashev J, Mueller B, Weder W, Burg G, Stahel RA, Dummer R, Trojan A. Human leukocyte antigen G up-regulation in lung cancer associates with highgrade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol 2001; 159: 817-824.
11. Baştürk B, Karakayalı F, Emiroğlu R, Sözer O, Haberal A, Bal D, Haberal M. Human leukocyte antigen-G, a new parameter in the follow-up of liver transplantation. Transplant Proc 2006; 38: 571-574.
12. Kleinberg L, Flørenes VA, Skrede M, Dong HP, Nielsen S, McMaster MT, Nesland JM, Shih IeM, Davidson B. Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Arch. 2006l; 449: 31-39.
13. Hansel DE, Rahman A, Wilentz RE, Shih IM, McMaster MT, Yeo CJ, Maitra A. HLA-G upregulation in pre-malignant and malignant lesions of the gastrointestinal tract. Int J Gastrointest Cancer 2005; 35: 15-23.
14. Singer G, Rebmann V, Chen YC, Liu HT, Ali SZ, Reinsberg J, McMaster MT, Pfeiffer K, Chan DW, Wardelmann E et al. HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res 2003; 9: 4460-4464.
15. Shih IM. Application of human leukocyte antigen-G expression in the diagnosis of human cancer. Hum Immunol 2007; 68: 272-276.
16. Kemp EH, Metcalfe RA, Watson PF, Weetman AP. HLA-G does not have a pathophysiological role in Graves disease. J Clin Pathol 2003; 56: 475-477.
17. Dardano A, Rizzo R, Polini A, Stignani M, Tognini S, Pasqualetti G, Ursino S, Colato C, Ferdeghini M, Baricordi OR et al. Soluble human leukocyte antigen-g and its insertion/ deletion polymorphism in papillary thyroid carcinoma: novel potential biomarkers of disease? J Clin Endocrinol Metab 2012; 97: 4080-4086.